Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.39 |
| ▸ | JAK3 | P52333 | 8/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394099 | 1.00 | JAK2 (0.39) | JAK2JAK3PTK2MAP4K1SYK | |
| SCHEMBL26072696 | 0.91 | SYK (0.36) | SYKHTR2AHTR2CSLC6A4PIM1 | |
| SCHEMBL29393810 | 0.91 | SYK (0.36) | SYKHTR2AHTR2CSLC6A4PIM1 | |
| SCHEMBL26072412 | 0.90 | JAK2 (0.42) | JAK2JAK3PTK2PTGS2 | |
| SCHEMBL29393641 | 0.90 | JAK2 (0.42) | JAK2JAK3PTK2PTGS2 | |
| SCHEMBL26072592 | 0.88 | MAP4K1 (0.38) | JAK2JAK3PTK2MAP4K1SYK | |
| SCHEMBL29396253 | 0.88 | MAP4K1 (0.38) | JAK2JAK3PTK2MAP4K1SYK | |
| SCHEMBL26072085 | 0.87 | TLR9 (0.41) | JAK2JAK3PTK2SYKDRD2 | |
| SCHEMBL29394205 | 0.87 | TLR9 (0.41) | JAK2JAK3PTK2SYKDRD2 | |
| SCHEMBL29393670 | 0.87 | MAP4K1 (0.38) | JAK2JAK3PTK2MAP4K1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | JAK2 137/4885JAK3 240/4885PTK2 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.